RnDCircle Logo
김탁 연구실
순천향대학교 의학과 김탁 교수
Antimicrobial stewardship
Antimicrobial resistance
Carbapenem-resistant
기본 정보
연구 분야
프로젝트
논문
구성원

김탁 연구실

순천향대학교 의학과 김탁 교수

김탁 연구실은 병원 감염과 항생제 사용의 관계를 중심으로 항생제 사용 중재(AMS)와 감염관리 전략을 연구합니다. 카바페넴 내성 세균의 항생제 감수성 및 유전형 정보를 기반으로 분자역학적 위험을 해석하고, 장기 추세 분석을 통해 유행 변화를 추적합니다. 또한 의료 제공자 설문 분석으로 안전한 주사 실행 요인을 규명하고 교육 효과를 평가합니다. 더불어 다제내성 Pseudomonas aeruginosa에서 박테리오파지 기반 치료가 항생제 감수성에 미치는 영향을 확인하는 실험 연구도 수행합니다.

Antimicrobial stewardshipAntimicrobial resistanceCarbapenem-resistantMolecular epidemiologyInfection control
대표 연구 분야
연구 영역 전체보기
다제내성 녹농균에서 박테리오파지 기반 치료와 항생제 감수성 변화 규명 연구 thumbnail
다제내성 녹농균에서 박테리오파지 기반 치료와 항생제 감수성 변화 규명 연구
Investigation of Phage-Based Therapeutics and Antibiotic Susceptibility Shifts in Multidrug-Resistan
연구 분야 상세보기
연구 성과 추이
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.

5개년 연도별 논문 게재 수

38총합

5개년 연도별 피인용 수

940총합
주요 논문
5
논문 전체보기
1
article
|
gold
·
인용수 0
·
2026
Reply: NDM-producing Multidrug-resistant Pseudomonas aeruginosa in Korea: A Growing Threat Requiring National Attention
Tark Kim, Yong Pil Chong
IF 2.9 (2026)
Infection and Chemotherapy
https://doi.org/10.3947/ic.2026.0020
MEDLINE
Public health
Disease
2
article
|
gold
·
인용수 0
·
2026
P-891. Antimicrobial Utilization Trend in Small Community Hospitals Supported by a Collaborative, Consultative Network in the Southeastern United States
Tark Kim, Elizabeth Dodds Ashley, Jeannette Bouchard, April Dyer, Melissa D Johnson, Angelina Davis, Anderson Dm
IF 3.8 (2026)
Open Forum Infectious Diseases
Abstract Background Antimicrobial stewardship programs (ASPs) are essential to reduce antimicrobial resistance, but small hospitals often face challenges in securing ASP expertise. A collaborative network model may help overcome this limitation. We analyzed the impact of changes in ASP expertise and implementation on antimicrobial utilization (AU) trends in small community hospitals (less than 100 beds) supported by the Duke Antimicrobial Stewardship Outreach Network (DASON). Methods We assessed the status of ASP expertise and implementation in hospitals with fewer than 100 beds who are members of the 48 hospital DASON network based on the 2021 and 2023 National Healthcare Safety Network (NHSN) annual surveys. AU data were obtained from the DASON database. Hospital were clustered into six groups in 2021 based on the composition of ASP expertise and implementation. Using the same clustering algorithm, hospitals were re-clustered in 2023. Within-hospital differences in implementation and expertise were categorized into worsened, no-change, and improved groups based on changes in their cluster assignments. A mixed-effects model was used to compare AU trends between groups, followed by post hoc analysis of slope changes from 2021 to 2023. Results Of the 15 DASON member hospitals with fewer than 100 beds, 7 had complete AU and implementation and expertise data for analysis. Two had an infectious diseases (ID) physician, one had an ID pharmacist and six received ID tele-services in 2021. Regarding ASP expertise changes, three , two , and two hospitals were categorized into worsened, no-change, and improved groups, respectively. For ASP implementation, four, one and two hospitals were categorized into worsened, no-change, and improved groups. Linezolid and carbapenem use significantly decreased in the improved expertise group compared to the worsened and no-change groups. In the improved implementation group, AU for hospital-onset infections and Gram-positive organisms decreased significantly. Additionally, use of antifungal agents, carbapenems, linezolid, and vancomycin significantly decreased. Conclusion Strengthening ASP implementation through a collaborative, consultative model may improve antimicrobial use even in small hospitals where securing expertise is challenging. Disclosures Elizabeth Dodds Ashley, PharmD, MHS, HealthtrackRx: Advisor/Consultant|UpToDate, Inc.: Author Royalties Melissa D. Johnson, PharmD MHS AAHIVP, Biomeme: Licensed technology, method to detect fungal infection|Biomeme: Licensed technology, method to detect fungal infection|Scynexis: Grant/Research Support|Scynexis: Grant/Research Support|UpToDate: Author Royalties|UpToDate: Author Royalties
https://doi.org/10.1093/ofid/ofaf695.1099
Antimicrobial stewardship
Outreach
Collaborative network
Cluster (spacecraft)
Health care
Pharmacist
3
review
|
gold
·
인용수 2
·
2025
Strengthening Antimicrobial Stewardship in Korea: Strategies to Address Workforce Gaps and Expand ASP Nationwide
Tark Kim, Rebekah W. Moehring, Elizabeth Dodds Ashley, Hyung-Sook Kim, Deverick J. Anderson
IF 2.9 (2025)
Infection and Chemotherapy
Given the global threat of antimicrobial-resistant organisms, an effective antimicrobial stewardship program (ASP) is essential. Infectious disease (ID) physicians and ID-trained pharmacists are prioritized as critical core members of ASP in hospital settings, but securing these ID-trained professionals in all settings is challenging. Alternative champions and personnel for implementation may be needed. This narrative review highlights the efficacy of ASP when non-ID-trained physicians and pharmacists are engaged in ASP, showcasing various studies demonstrating significant improvements in antimicrobial utilization, cost, and patient outcomes. Additionally, it discusses the impact of network-based models, such as the Duke Antimicrobial Stewardship Outreach Network, which provides structured support and resources to lower-resourced hospitals to ensure the successful implementation of ASP. Ultimately, this narrative review provides insights into how to structure accountability and pharmacy/stewardship expertise in establishing and expanding ASP nationwide in Korea, where ASP is still in its early stages. In addressing this issue, government initiatives to actively support this effort are essential, and striving to develop evidence-based policies is necessary.
https://doi.org/10.3947/ic.2024.0135
Medicine
Antimicrobial stewardship
Workforce
Stewardship (theology)
Family medicine
Intensive care medicine
Environmental health
Economic growth
Antibiotic resistance
Antibiotics
최신 정부 과제
2
과제 전체보기
1
2023년 5월-2026년 2월
|45,633,000
광범위내성 녹농균에서 박테리오파지가 항생제 감수성에 미치는 영향 확인
광범위 내성 녹농균에 대하여 박테이로파지 치료가 항생제 감수성과 치료효과를 개선시키는지를 확인하여 다제내성녹농균의 치료제로서 박테리오파지의 가능성을 확인.
다제내성
녹농균
박테리오파지
치료
2
2023년 5월-2026년 2월
|57,041,000
광범위내성 녹농균에서 박테리오파지가 항생제 감수성에 미치는 영향 확인
광범위 내성 녹농균에 대하여 박테이로파지 치료가 항생제 감수성과 치료효과를 개선시키는지를 확인하여 다제내성녹농균의 치료제로서 박테리오파지의 가능성을 확인.
다제내성
녹농균
박테리오파지
치료

주식회사 디써클

대표 장재우,이윤구서울특별시 강남구 역삼로 169, 명우빌딩 2층 (TIPS타운 S2)대표 전화 0507-1312-6417이메일 info@rndcircle.io사업자등록번호 458-87-03380호스팅제공자 구글 클라우드 플랫폼(GCP)

© 2026 RnDcircle. All Rights Reserved.